BRÈVE

sur Biophytis (EPA:ALBPS)

Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol

Biophytis SA, a Paris and Cambridge-based biotech firm, recently showcased its Phase 3 study protocol for testing the efficacy of RuvembriTM in sarcopenia treatment. This announcement was made at the International Conference on Frailty and Sarcopenia Research in Albuquerque, NM. The company's previous Phase 2 study, SARA-INT, illustrated promising results in enhancing physical performance in sarcopenic patients.

RuvembriTM's Phase 3 trial, named SARA-31, aims to enroll 932 participants in a randomized, double-blind, placebo-controlled study. This follows encouraging outcomes and insights from previous research, including SARA-INT, SPRINTT, and LIFE studies. Approval for the study has been secured in both Belgium and the United States. CEO Stanislas Veillet expressed optimism about the development and market potential of RuvembriTM for sarcopenia, highlighting the active search for pharmaceutical partnerships.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Biophytis